熱門資訊> 正文
FDA拒绝批准先导药物，学者洛克股价下跌
2025-09-23 19:45
- Scholar Rock (NASDAQ:SRRK) shares fell ~15% in the premarket on Tuesday after the biotech said that the U.S. FDA has issued a Complete Response Letter (CRL) in connection with its marketing application for its lead drug, apitegromab, declining its availability in the U.S.
- The company submitted a Biologics License Application with the FDA early this year to obtain the agency’s approval for apitegromab to treat spinal muscular atrophy, a rare neuromuscular disease.
- Sending a CRL, the agency has rejected the BLA, citing findings its investigators noticed during a visit to a third-party fill-finish facility in Indiana that Danish drugmaker Novo Nordisk (NVO) acquired in December.
- The CRL didn’t indicate any other approvability issues related to the drug, the Cambridge, Massachusetts-based biotech said, adding that it will resubmit the BLA once Catalent Indiana resolves the FDA observations.
More on Scholar Rock
- Scholar Rock Holding: Upcoming Milestone Approaches
- Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript
- Scholar Rock shares close 6% higher after Leerink initiates at outperform
- Scholar Rock jumps following Regeneron Eylea update
- Seeking Alpha’s Quant Rating on Scholar Rock
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
